Molecularly targeted therapy in renal cell carcinoma: where do we go from here? [electronic resource]
Producer: 20070308Description: 1753-60 p. digitalISSN:- 1744-8328
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Benzenesulfonates -- therapeutic use
- Bevacizumab
- Carcinoma, Renal Cell -- blood supply
- Case Management -- trends
- Clinical Trials as Topic
- Combined Modality Therapy
- Cytokines -- therapeutic use
- Humans
- Indoles -- therapeutic use
- Kidney Neoplasms -- blood supply
- Neovascularization, Pathologic -- drug therapy
- Nephrectomy -- methods
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Pyridines -- therapeutic use
- Pyrroles -- therapeutic use
- Sirolimus -- analogs & derivatives
- Sorafenib
- Sunitinib
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.